Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

48.87 +0.81 (+1.69%)
Streaming Delayed Price Updated: 10:26 AM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 55,686
Open 48.54
Bid (Size) 48.98 (100)
Ask (Size) 49.09 (100)
Prev. Close 48.06
Today's Range 48.19 - 49.20
52wk Range 24.10 - 60.34
Shares Outstanding 54,026,103
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platform 
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-5.2%
-5.2%
1 Month
+17.9%
+17.9%
3 Month
+39.6%
+39.6%
6 Month
+51.2%
+51.2%
1 Year
-14.5%
-14.5%

More News

Read More
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move ↗
Via Stocktwits
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday ↗
Via The Motley Fool
News headline image
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Emerges as a Technical Breakout Candidate ↗
Via Chartmill
News headline image
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reports Q3 2025 Earnings Miss ↗
Via Chartmill
Topics Earnings
News headline image
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is Crinetics Pharmaceuticals Stock a Buy? ↗
Via The Motley Fool
News headline image
FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Friday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday ↗
Via Benzinga
Topics Stocks
News headline image
Assessing Crinetics Pharmaceuticals: Insights From 4 Financial Analysts ↗
Via Benzinga
News headline image
Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism ↗
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Crinetics Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Crinetics Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Crinetics Pharmaceuticals, Inc. - Common Stock trade on?
Crinetics Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock is CRNX on the Nasdaq Stock Market
What is the current price of Crinetics Pharmaceuticals, Inc. - Common Stock?
The current price of Crinetics Pharmaceuticals, Inc. - Common Stock is 48.87
When was Crinetics Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Crinetics Pharmaceuticals, Inc. - Common Stock was at 12/11/25 10:26 AM ET
What is the market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock is 2.64B
How many shares of Crinetics Pharmaceuticals, Inc. - Common Stock are outstanding?
Crinetics Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.